Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: The xelbevoct study
pdf
10
374 KB
0
0
4.4 (
7 lượt)
Nhấn vào bên dưới để tải tài liệu
Để tải xuống xem đầy đủ hãy nhấn vào bên trên
Chủ đề liên quan
BMC Cancer
Pancreatic endocrine tumor
Well-to-moderately differentiated
Neuroendocrine neoplasms
Vascular endothelial growth factor
Progression-free survival
Nội dung
This site is protected by reCAPTCHA and the Google
Privacy Policy
and
Terms of Service
apply.